These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas. Hwang HC, Pyott S, Rodriguez S, Cindric A, Carr A, Michelsen C, Thompson K, Tse CH, Gown AM, Churg A. Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815 [Abstract] [Full Text] [Related]
3. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A. Am J Surg Pathol; 2015 Jul; 39(7):977-82. PubMed ID: 25634745 [Abstract] [Full Text] [Related]
4. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens. Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A. Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191 [Abstract] [Full Text] [Related]
5. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, Barbareschi M, Giuliani S, Cavazza A, Marchetti G, Vermi W, Facchetti F. Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455 [Abstract] [Full Text] [Related]
7. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma. Pillappa R, Maleszewski JJ, Sukov WR, Bedroske PP, Greipp PT, Boland JM, Yi ES, Peikert T, Aubry MC, Roden AC. Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876 [Abstract] [Full Text] [Related]
8. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Chevrier M, Monaco SE, Jerome JA, Galateau-Salle F, Churg A, Dacic S. Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499 [Abstract] [Full Text] [Related]
14. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens. Berg KB, Churg AM, Cheung S, Dacic S. Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740 [Abstract] [Full Text] [Related]
16. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, Gilly FN, Foll M, Fernandez-Cuesta L, Brevet M. J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829 [Abstract] [Full Text] [Related]
18. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma. Wu D, Hiroshima K, Yusa T, Ozaki D, Koh E, Sekine Y, Matsumoto S, Nabeshima K, Sato A, Tsujimura T, Yamakawa H, Tada Y, Shimada H, Tagawa M. Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708 [Abstract] [Full Text] [Related]